PURPOSE: To describe a citrate regional anticoagulation (CRA) protocol for patients with acute renal failure and contraindications to heparin who require continuous renal replacement therapy (CRRT), using only commercially available solutions, for units that do not want or cannot prepare extemporaneously made solutions. MATERIALS AND METHODS: Case report and series from a medical/surgical intensive care unit of a university teaching hospital. A CRA protocol was developed by using only commercially available solutions. Five dialysis-specific clinical parameters were identified to allow simplified measurement and control. RESULTS: There was a dramatic improvement of dialysis filter survival in the index patient that was seen in the subsequent patients receiving CRA. This was accompanied by excellent control of the clinical and biochemical parameters as well as nursing acceptance and ownership of the protocol. CONCLUSION: It is possible to provide safe and effective CRA with only commercially available solutions. The protocol is applicable to most patients requiring CRRT. Copyright 2003 Elsevier Inc. All rights reserved.
PURPOSE: To describe a citrate regional anticoagulation (CRA) protocol for patients with acute renal failure and contraindications to heparin who require continuous renal replacement therapy (CRRT), using only commercially available solutions, for units that do not want or cannot prepare extemporaneously made solutions. MATERIALS AND METHODS: Case report and series from a medical/surgical intensive care unit of a university teaching hospital. A CRA protocol was developed by using only commercially available solutions. Five dialysis-specific clinical parameters were identified to allow simplified measurement and control. RESULTS: There was a dramatic improvement of dialysis filter survival in the index patient that was seen in the subsequent patients receiving CRA. This was accompanied by excellent control of the clinical and biochemical parameters as well as nursing acceptance and ownership of the protocol. CONCLUSION: It is possible to provide safe and effective CRA with only commercially available solutions. The protocol is applicable to most patients requiring CRRT. Copyright 2003 Elsevier Inc. All rights reserved.
Authors: Jeffrey F Barletta; Gina-Marie Barletta; Patrick D Brophy; Norma J Maxvold; Richard M Hackbarth; Timothy E Bunchman Journal: Pediatr Nephrol Date: 2006-04-19 Impact factor: 3.714
Authors: Feng Ding; Joon Ho Song; Ju Young Jung; Liandi Lou; Min Wang; Linda Charles; Angela Westover; Peter L Smith; Christopher J Pino; Deborah A Buffington; H David Humes Journal: PLoS One Date: 2011-04-14 Impact factor: 3.240
Authors: Anne Kit-Hung Leung; Hoi-Ping Shum; King-Chung Chan; Stanley Choi-Hung Chan; Kang Yiu Lai; Wing-Wa Yan Journal: Crit Care Res Pract Date: 2013-01-28